Avid Bioservices, Inc. (CDMO)
| Market Cap | 838.15M |
| Revenue (ttm) | 72.59M |
| Net Income (ttm) | -5.27M |
| Shares Out | 56.66M |
| EPS (ttm) | -0.08 |
| PE Ratio | n/a |
| Forward PE | 78.74 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $13.84 |
| Previous Close | $14.01 |
| Change ($) | -0.17 |
| Change (%) | -1.21% |
| Day's Open | 14.07 |
| Day's Range | 13.77 - 14.20 |
| Day's Volume | 418,794 |
| 52-Week Range | 3.15 - 14.20 |
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...
TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...
TUSTIN, Ca., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to ...
TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...
The company reported great fiscal 2021 Q2 results.
Avid Bioservices' (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript
Shares of Avid Bioservices (NASDAQ:CDMO) moved higher by 8.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 133.33% over the past ...
-- Recorded Second Quarter Revenue of $ 21 .1 Million -- -- Signed $28 Million in Business Orders and Ended the Quarter with a Backlog of $67 Million --
TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...
TUSTIN, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working ...
TUSTIN, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual...
TUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) worki...
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q1 2021 Results - Earnings Call Transcript
Shares of Avid Bioservices (NASDAQ:CDMO) rose 6.81% after the company reported Q1 results.
-- Recorded First Quarter Revenue of $25.4 Million -- -- S igned Three New Customers and Project Expansion Orders with Current Customers for $20 Million --
TUSTIN, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...
TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...
TUSTIN, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...
TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...
Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeu...
Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The company still had significant production problems. But it also picked up a lot of new business in Q4.
Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.
Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript
-- Appointed Nicholas Green as President and Chief Executive Officer -- -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million --
Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion Seasoned Executive Brings Mor...
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances Full Service “Sequence-to-Man...
These two businesses offer compelling growth potential, but one has yet to deliver on its promise and the other just became more complicated thanks to the coronavirus pandemic.
TUSTIN, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) worki...
Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry
The drug manufacturer encountered an operational setback, which forced it to slash revenue guidance.
Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q3 2020 Results - Earnings Call Transcript
Avid Bioservices (CDMO) delivered earnings and revenue surprises of -100.00% and -19.14%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the...
Avid Bioservices (NASDAQ:CDMO) reported Q3 results. Quarterly Results • Earnings per share decreased 20% year over year to a loss of $0.06, which missed the estimate by $0.02.
TUSTIN, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) worki...
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience Company Adds Seasoned Professional with Over 20 Years of Commercial Operatio...
After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...
These two small-cap stocks are risky, but not as risky as penny stocks. And buying a small stake in either company could actually pay off for patient investors.
The drug manufacturing company reported operating results for its fiscal second quarter.
Avid Bioservices, Inc. (CDMO) CEO Rick Hancock on Q2 2020 Results - Earnings Call Transcript
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 25.00% and 23.74%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the st...
-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed --
TUSTIN, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) workin...
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Senior Executive with More than 25 Years of Biopharmaceutical Industry Manufacturing Operations Experience Senior Executive with More than 25 Years of Biopharmaceutical Industry Manufacturing ...
Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories Company to Host Open House to Celebrate Official Launch of Newly Expanded Laboratories
Avid Bioservices, Inc. (CDMO) CEO Rick Hancock on Q1 2020 Results - Earnings Call Transcript
Shares jump after the company receives some love from the analyst community.
About CDMO
Avid Bioservices, a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also prov... [Read more...]
| Industry Biotechnology | Founded 1981 |
| Stock Exchange NASDAQ | Ticker Symbol CDMO |
Financial Performance
In 2020, CDMO's revenue was $59.70 million, an increase of 11.38% compared to the previous year's $53.60 million. Losses were -$10.47 million, 148.3% more than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for CDMO stock is "Strong Buy." The 12-month stock price forecast is 14.33, which is an increase of 3.54% from the latest price.